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Despite important human and financial resources and considerable accumulation of scientific publications, patents,
and clinical trials, cancer research has been slow in achieving a therapeutic revolution similar to the one that occurred
in the last century for infectious diseases. It has been proposed that science proceeds not only by accumulating data but
also through paradigm shifts. Here, we propose to use the concept of ‘paradigm shift’ as a method of investigation
when dominant paradigms fail to achieve their promises. The first step in using the ‘paradigm shift’ method in cancer
research requires identifying its founding paradigms. In this review, two of these founding paradigms will be
discussed: (i) the reification of cancer as a tumour mass and (ii) the translation of the concepts issued from infectious
disease in cancer research. We show how these founding paradigms can generate biases that lead to over-diagnosis
and over-treatment and also hamper the development of curative cancer therapies. We apply the ‘paradigm shift’
method to produce perspective reversals consistent with current experimental evidence. The ‘paradigm shift’ method
enlightens the existence of a tumour physiologic–prophylactic–pathologic continuum. It integrates the target/anti-
target concept and that cancer is also an extracellular disease. The ‘paradigm shift’method has immediate implications
for cancer prevention and therapy. It could be a general method of investigation for other diseases awaiting therapy.
[Wion D, Appaix F, Burruss M, Berger F and van der Sanden B 2015 Cancer research in need of a scientific revolution: Using ‘paradigm shift’ as a
method of investigation. J. Biosci. 40 657–666] DOI 10.1007/s12038-015-9543-3
1. Introduction
But every time I read the papers, that old feeling comes on,
We‘re waist deep in the Big Muddy…’
Opening a paper on cancer research with the lyrics of a Pete
Seeger’s protest song, considered symbolic of the Vietnam
war and the President Lyndon Johnson’s policy of escalation
(http://en.wikipedia.org/wiki/Waist_Deep_in_the_Big_
Muddy), may seem inappropriate at first glance. However,
viewing cancer research as a war on cancer is a common
metaphor (Hanahan 2014). President Richard Nixon
signed the National Cancer Act of 1971, beginning the
‘War on Cancer’. Forty years later, we have observed an
escalation in cancer research funding and therapy costs.
Impressive advances in our understanding of the mecha-
nisms of the disease have also occurred. This led to the
discovery of Imatinib in 1996, for example, which proves
the principle for targeted therapy in chronic myeloid
leukaemia (Druker 2009). More than 15 years have
passed and therapeutic breakthroughs due to targeted
therapies remain an exception. The thousands of scientific
publications indexed in bibliographic databases such as
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PubMed have not significantly changed the course of
several solid tumours including brain, liver and pancreatic
cancers (Berrino et al. 2007; De Angelis et al. 2014;
Hanahan 2014). Bibliometric indexes are not therapeutic
indexes, and current paradigms used in cancer research
could be productive in terms of publications and patents
while leading to therapeutic impasses.
In some ways, we are behaving like flying insects
trying to escape from a closed room. Attracted by the
outside light, insects continuously fly towards the glass
of the window, while it would be counterintuitive to go
through the darkness of the chimney flue. Science also
progresses by reversing perspectives through the formu-
lation of testable counterintuitive hypotheses. It is time
for a scientific revolution in cancer research. This could
be done by using the concept of ‘paradigm shift’ as a
method of investigation
2. Epistemoligical considerations
It is in the mind of the researcher, in his intellectual
approach itself that there are obstacles to the advance-
ment of knowledge.
Science does not only progress by accumulating data and
analyses in established conceptual frameworks but also
through paradigm shifts. A paradigm shift does not neces-
sarily call into question the validity of experimental data.
Changes in relationships between data may create paradigm
shifts. The role of paradigm changes in the progress of
science has long been discussed through the concepts of,
for example, epistemological obstacle and scientific revolu-
tion (Kuhn 1962a, b; Bachelard 1938). For Bachelard, ‘it is
in the mind of the researcher, in his intellectual approach
itself that there are obstacles to the advancement of knowl-
edge’ (Bachelard 1938). These obstacles are of course invol-
untary. Kuhn also discusses the importance of paradigm
change through the concept of scientific revolution (Kuhn
1962a, b). He distinguishes normal science from extraordi-
nary science. Normal science ‘is directed to the articulation
of those phenomena and theories that the paradigm already
supplies’ (Kuhn 1962b). It is a puzzle-solving process es-
sential to the development of science. An example of normal
science is the discovery of the elements that filled empty
spaces in the periodic table (Kuhn 1962a). Normal science is
exploitation of the paradigms created by extraordinary sci-
ence. One limitation of normal science is that it tends to
discover what it expects to discover. Hence, ‘failure to solve
part of the puzzle is likely to discredit first the scientist and
not the theory’ (Kuhn 1962b). In normal science, scientists
put themselves in a state of voluntary servitude. In return,
they are rewarded, for example, in the form of academic
careers and grants. On the other hand, extraordinary science
may be viewed as a catharsis-like process.
When a study fails to obtain its anticipated results and this
anomaly persists, a crisis may occur. A possible way to
resolve such a crisis is to adopt new perspectives through
paradigm shifts. Transition from a Ptolemaic cosmology to a
Copernican one, replacement of the Phlogiston theory by the
Lavoisier’s oxygen theory of combustion, or the Pasteur and
Koch germ theory of diseases can be interpreted in term of
scientific revolutions. Importantly, in Kuhn’s view ‘every
problem that normal science sees as a puzzle can be seen
from another view as a counter-instance and thus a source of
crisis’. Equally important is the reiteration of the importance
and validity of the ‘puzzle-solving’ approach in the devel-
opment of science. Although influential, the concept of
‘scientific revolution’ is not exclusive. For example,
Popper’s falsifiability, in which science proceeds by conjec-
tures and refutations is another way to account for scientific
progress. Serendipity may also explain some discoveries.
Now, let us consider the hypothesis that the difficulty of
cancer research to achieve some of its therapeutic expectan-
cies is interpretable as a of crisis, that this crisis could be
solved using a paradigm shift, and that one of the anomalies
or epistemological obstacles we have to deal with is the way
we perceive the cancer cell itself.
3. Cancer as a scientific object and its ‘space-time’
framework
Objectivity is the founding postulate of science. Science is
objective with regard to its method and its objects, but
scientific inquiry is a human process. Archetypes, themata
(Holton 1975), academism, and fashion (Kuhn 1962a, b;
Bachelard 1938) operate in scientists’ minds without their
being aware of it. Such biases are not negative per se. They
are intrinsic to the process of discovery. Some of them fuel
creativity and have heuristic value. They also impact the
social and cultural aspects of science. Nevertheless, uniden-
tified biases may also hinder rather than advance scientific
progress. This occurs when biases lead to a conceptual
impasse. For a scientist, characterization and analysis of
biases that belong to the paradigm he or she uses should be
an integral part of the experimental procedure.
To achieve identification and analysis of the conse-
quences of some of these biases in cancer research, we have
chosen to consider cancer as a scientific object that emerged
in the early 20th century in a ‘space-time’ framework.
‘Oncology’ comes from ancient Greek ‘ γκος’ (onkos)
meaning ‘mass’. The reification of the disease of cancer as
a tumour mass provides the ‘space’ part of our framework.
The other part, ‘time’, is the late 19th century with Pasteur
and Koch’s germ theory of disease. These choices are not
– Gaston Bachelard
658 Didier Wion et al.
J. Biosci. 40(3), September 2015
exclusive. Other founding paradigms could be considered,
such as the institution of cellular pathology by Virchow.
More recently, the discovery of oncogenes and anti-
oncogenes that defined cancer as a gene-driven disease ac-
cording to the somatic mutation theory of carcinogenesis
(Stehelin et al. 1976; Bishop 1983) could also be analysed
for the possible biases they have introduced (Sonnenschein
and Soto 2000; Soto and Sonnenschein 2014; Weinberg
2014). Significantly, methods and concepts of molecular
genetics have deep foundations in microbiology.
4. The cancer cell: A legacy of microbiological medicine
One of the things a scientific community acquires with
a paradigm is a criterion for choosing problems that,
while the paradigm is taken for granted, can be as-
sumed to have solutions.
In the ‘space-time’ framework proposed to account for the
emergence of cancer as a scientific object, the time we selected
is the 19th century of Pasteur and Koch microbiology. We
chose this period because microbiology and the germ theory of
disease provided both the conceptual (Koch’s postulates), the
methodological (cell culture), and the therapeutic (cytotoxic
drugs) grounds on which cancer cell research has been devel-
oped (Garcion et al. 2009). Historically, experimental cancer
research focused on the isolation and culture of cancer cells as
the causal agents of cancer, just as microbiologists focused at
the same time on the isolation and culture of microbes as
causal agents for infectious diseases. At this time, mammalian
cell culture appeared ‘to be no more difficult than the cultiva-
tion of many microbes… and [will be] of great value in the
study of the problem of cancer’ (Carrel and Burrows 1910).
During the same period, another Nobel Prize recipient, Peyton
Rous, viewed cell culture as ‘a method whereby living tissue
cells can be plated out in a culture medium just as bacteria’
(Rous and Jones 1916). Likewise, in 1958, Eagle, in his
presidential address at the 58th annual meeting of the Society
of American Bacteriologists, noted, regarding nutritional cell
culture requirements, ‘at each step we fall back upon the
prototype experiments of the microbiologist. But it is not only
the techniques which are similar, but also the findings’ (Eagle
1958). This commitment to microbiological paradigms fo-
cused cancer research on the characterization of cancer cells
or cancer stem cells as microbe avatars. Implanting cultured
cancer cells in animals to reproduce tumour growth is just the
translation of one of the founding experiments of the germ
theory of disease, i.e. the injection of microbes previously
amplified in cultures into animals to reproduce infectious
diseases (Garcion et al. 2009).
All these concerns do not question the interest of these
approaches. The application of microbiological paradigms to
cancer research led to the discovery of the oncogenic virus.
Likewise, the importance of the cancer cell as a necessary
causal agent in the development of the disease has been
experimentally demonstrated. However, infectious disease
and cancer can also be viewed as two bio-logically incom-
mensurable diseases requiring alternative experimental and
theoretical frameworks (Garcion et al. 2009). The cell cul-
ture method derived from microbiology has given the cancer
cell cult status. The tendency of experimental cancer re-
search to transform its purposes to make them fit into the
experimental and conceptual frameworks of medical micro-
biology has not been sufficiently considered. One conse-
quence of this dependence on microbiological paradigms is
that cancer therapies, such as chemotherapy, focused on the
destruction of cancer cells in the same way that antibiotics
target bacteria, with the same consequences for the emer-
gence of drug-resistant variants. Another consequence was
underestimating for a long time other necessary causal
agents such as non-tumourigenic cells and, as discussed
below, the extracellular matrix (ECM) (Bissell and
Radisky 2001).
5. Tumour: Symptom versus disease
The other component of the proposed ‘space-time’ frame-
work is space. In the case of solid tumours, the cancer
disease was primitively conceptualized in space as a tumour
mass. This led to the clinical assumption that the tumour
mass is the disease, with the consequence of legitimizing
therapies focusing on tumour eradication. However, the al-
ternative view of considering the tumour not as the disease
but as a symptom of the disease has been given scant
attention. This small paradigm shift radically changes views
on what the disease is and what its therapy should be.
A symptom, once interpreted as a clinical sign by the
physician, marks a disease, but it is not necessarily its causal
factor. From a functional viewpoint, symptoms can also be
interpreted as physiological means of fighting diseases (con-
sider, for example, inflammation, fever, diarrhea, etc.).
Suppressing symptoms can be viewed by patients and from
a clinical standpoint as curing the disease. Arguing that
suppressing symptoms suppresses the disease, however, is
debatable. It is critical to discern from among the symptoms
used to define a disease, the ones are the direct cause of the
disease from those that are part of defence mechanisms.
From a therapeutic standpoint, the former category of symp-
toms should be eradicated whereas the latter should be
promoted. Cancer cells can be assigned to the first category.
The situation might be somewhat different with the tumour,
at least in the early phase.
Cancer, as a disease, is a process. During this process a
physiological response developed as initially as a defence
mechanism can be perceived as a causal symptom if it fails
– Thomas Kuhn
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to halt the progression of the disease or if its prophylactic
function is perverted. The causal relationships between can-
cer as a disease and tumour as a symptom are deeply
intertwined. Thus, it is difficult to imagine tumour formation
as a defence mechanism whose dysfunction becomes a nec-
essary causal factor in the course of the cancer process.
When clinicians look at the disease progression, biologists
should look at defence mechanisms for fighting the disease
and enabling organism survival. Cancer cells are subjected to
pressure selection and somatic evolution. However, cancer
cells do not survive patients. Mutant cancer clones evolve on
the timescale of the disease. That is the difference between
organism-level and somatic cancer cell-level evolution. This
is an additional difference between cancer and infectious
diseases. Microbes are organisms that survive patient death
because of their contagious nature. In cancer disease, the
evolutionary process at the organism-level has to be viewed
not as somatic mutations but as defence mechanisms against
cancer cell proliferation and spreading. Accumulating evi-
dence, presented below, suggests that one of these prophy-
lactic mechanisms is the tumour itself.
6. The paradigm shift: Tumour function
as prophylactic and cancer as a defect of tumour function
– the tumour continuum
In learning a paradigm the scientist acquires theory,
methods, and standards together, usually in an inex-
tricable mixture. Therefore, when paradigms change,
there are usually significant shifts in the criteria deter-
mining the legitimacy both of problems and of pro-
posed solutions.
In cancer, a defect in a physiological process does not neces-
sarily suppress the function of the process but can generate a
novel function involved in the progression of the disease
(Nugue and Wion 2012). Let us consider the counterintuitive
hypothesis that (i) tumour physiological function is a tissue
defence mechanism against cancer cells and that (ii) defects in
this physiological process result in the disease of cancer. If the
physiological functions of the tumour are both to confine
cancer cells in a location and to maintain them in a dormant
state, just as stem cell niche controls stem cell homeostasis,
then failure of this prophylactic function would result in cancer
cell invasion and proliferation. These are precisely the hall-
marks of cancer disease.
In this paradigm shift, tumour formation is viewed as the
result of an evolutionary process whose initial aim is to stall
the proliferation and the dissemination of cancer cells. In
other words, cancer disease is the perversion of the tumour
prophylactic potential into a pathologic process. A tumour is
no longer an entity but a process. In the early stage of
malignancies, tumour formation acts as a cancer-
suppressing process. There is a continuum between prophy-
lactic and pathologic tumours. Both clinical observations and
experimental findings support this paradigm shift, as we will
explore further in the following section.
7. The prophylactic potential of tumours: Clinical
observations
The prophylactic tumour concept can account for a huge
amount of observations reporting that some cancers can
unexpectedly stop growing or even regress. Tumour matu-
ration, cancer of unknown primary site, latent carcinoma and
tumour dormancy are some examples.
7.1 Tumour maturation
The observation of tumour maturation is not new. It was
already described 45 years ago as a rare reversal of the
tumour process involved in the spontaneous regression of
some cancers (Smithers 1969). This clinical observation
could be reminiscent of the reversion of the cancer cell
phenotype experimentally observed in vivo after implanta-
tion of teratocarcinoma cells in normal mouse blastocyst
(Mintz and Illmensee 1975). Maturation process has also
been observed following implantation of a transformed he-
patic cell line in the liver (Coleman et al. 1993) and with
carcinogenic mammary cells implanted in mammary glands
(Booth et al. 2011). It is important to note that tumour
maturation is usually interpreted as the reversal of the tu-
mour process, not as the recovery of a tumour prophylactic
function. This point is critical. It illustrates how the words
used to describe a phenomenon (here, ‘reversal’ vs ‘recov-
ery’) are embedded in the paradigm used and affect both
experimental designs and interpretations. Viewing tumour
maturation as a reversal or as a recovery can be considered
as a vocabulary matter. This could be also a tipping point.
7.2 Cancer of unknown primary site
Cancer of unknown primary site (CUP) is a heterogeneous
group of tumours that accounts for 3–5% of cancer (Morris
et al. 2010). It is diagnosed when metastases are detected in
the lack of detectable primary tumour using a standard
diagnostic approach (Pavlidis and Pentheroudakis 2012).
Although immunohistochemistry and transcriptomic profil-
ing can now assign the tissue of origin, CUP is still consid-
ered a ‘biological mystery’ (Greco 2014). In the new
paradigm proposed, CUP would result from partial failure
of the prophylactic tumour function, which would have
limited both cancer cell proliferation and dissemination. In
CUP, the primary tumour would have been unable to avoid
– Thomas Kuhn
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the early spread of metastasizing cancer cells while being
successful in limiting cancer cell proliferation locally in the
primary site either through tumour maturation/regression or
through the process of dormancy.
7.3 Latent carcinoma
Latent carcinoma, also viewed as ‘cancer without disease’
(Folkman and Kalluri 2004), was first described in the mid-
dle of the 20th century from a routine necropsy in the
absence of clinically identified carcinoma (Andrews 1949;
Franks 1954). These subclinical cancers meet the patholog-
ical definition of cancer, but they have not grown to cause
symptoms (Welch and Passow 2014). For that reason, the
term ‘tumour without disease’ might be preferred. This war-
rants the distinction between ‘tumour’ and ‘cancer’.
Pathologic tumours constitute cancer disease. Prophylactic
tumours result in latent carcinoma. These seemingly implau-
sible cancers have been a provocative but relatively marginal
issue for a long time. This was in part due to the absence of
an adequate corresponding theoretical framework able to
explain them. The situation recently changed when it became
apparent that (i) donor-related transmission of cancer can
occur after transplantation of an apparent disease-free organ
several years after the removal of a primary carcinoma in the
donor (Strauss and Thomas 2010) and (ii) latent carcinoma
commonly encountered for many cancers including prostat-
ic, mammary and thyroid cancers lead to over-diagnosis and
over-treatment (Esserman et al. 2014; Welch and Passow
2014). Indeed, current progress in biological sciences and
technology now allow the detection of anomalies which are
either silent for the patient or not readily observable in
clinical examination. Strong arguments favour the role of
tissue micro-environment in restraining cancer progression
(Bissell and Hines 2011). Mechanisms involved in these
processes are progressively revealed and are part of the
concept of tumour dormancy, as detailed below.
7.4 Tumour dormancy
In 1954 the expression ‘dormant cancer cell’ was coined by
Hadfield to describe cancer cells that are ‘in a state of
temporary mitotic arrest, no matter how long the period
may be’ (Hadfield 1954). Nowadays, the term tumour dor-
mancy is used for delayed recurrence (>5 years) due to the
long-term persistence following treatment of occult cancer
cells or micro-metastases. It is commonly observed in many
patients with breast, prostate, kidney cancers or melanoma.
Tumour dormancy in the recurrence of cancer in patients
already diagnosed for a primary cancer corresponds to me-
tastasis dormancy. More than a century of clinical observa-
tions demonstrate that metastasis dormancy can be
suppressed following surgical resection of the primary tu-
mour (Demicheli et al. 2008) . Of course, this does not deny
the utility of tumour resection, just as over-diagnosis, does
not deny the importance of cancer screening. Nevertheless, it
provides further evidence for the existence of a tumour
prophylactic potential.
In its broad sense, tumour dormancy includes single cell
and micro-metastases dormancy. The mechanisms involved
in single cancer cell and micro-metatstasis dormancy are not
identical. Single cell dormancy is usually considered as due
to cell-cycle arrest. In contrast, micro-metastasis also in-
cludes a balance between proliferation and apoptosis
(Holmgren et al. 1995). This is the point; in micro-
metastasis or latent carcinoma dormancy, what is dormant
is the disease, not the tissue or the cancer cell. Tumour
dormancy is an active process. A cancer cell enters dorman-
cy as a consequence of inhibitory signals. Paradoxically,
such signals can be triggered by oncogenes in the process
called oncongene-induced senescence (OIS) (Serrano et al.
1997; Collado and Serrano 2010). Other signals, such as
BMP or neoangiogenesis blocking agents such as
angiostatin, endostatin (O’Reilly et al. 1994; Gately et al.
1996; Nyberg et al. 2005) and thrombospondin-1 (Good
et al. 1990; Naumov et al. 2006; Bissell and Hines 2011),
are produced by tumour or cancer cells. The idea that the
normal tissue micro-environment can act as a barrier to
tumourigenesis is now widely accepted (Bissell and Hines
2011). The new paradigm we propose goes one step forward.
It suggests that tumour formation is initially a defence mech-
anism against cancer cell spreading and proliferation. Cancer
is the result of the failure of the tumour to fulfill its prophy-
lactic function. In this model, latent carcinoma and micro-
metastasis correspond to the time period during which the
tumour exerts its physiological/prophylactic function of can-
cer cell containment. This reversal of perspective is impor-
tant. Tumour growth is usually considered an active process
and tumour dormancy is viewed as a passive one. For that
reason, tumour dormancy is viewed as a failure of the tu-
mour process. Associating growth with success, however, is
a sociocultural bias, not a biological conclusion. In the
proposed paradigm shift, in which the tumour protects the
organism from cancer cell proliferation and dissemination,
dormancy is the relevant successful active physiological
process. For that reason, the term ‘cancer dormancy’ should
be preferred to ‘tumour dormancy’. How many experiments
with rodents failing to develop experimental tumours were
or still are discarded without further analysis, while they may
be developing one of the most critical anti-cancer biological
processes? We will never know. As Barber remarked, ‘sci-
entists are sometimes the agents, sometimes the objects, of
resistance of their own discoveries’ (Barber 1961).
Viewing tumour dormancy as an active physiological
process offers the opportunity to understand the induction
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of the dormant state and to reproduce it for therapeutic
purposes. It provides also a conceptual framework for ad-
dressing over-diagnosis and over-treatement.
8. The prophylactic potential of tumour: Experimental
evidences
Viewing tumours as evolutionary defence mechanisms of the
organism against cancer cells should not be viewed as a
provocative posture. The prophylactic potential of tumour
is not only suggested by clinical observations, but is now
supported by experimental and mechanistic evidences just
waiting to be gathered in a unifying paradigm.
8.1 Protective function of the tumour mass against
metastasis growth
The first observation that could have suggested the prophy-
lactic potential of tumours can be traced back to 1905 in the
Ehrlich and Apolant’s experiments of double inoculation
(cited by Demicheli (Demicheli et al. 2008)). They observed
that an experimental primary tumour delayed the growth of a
secondary one (cited by Demicheli (Demicheli et al. 2008)).
Their interpretation was that the already established tumour
withdraws special nutritive substances required for the sec-
ondary tumour growth (Demicheli et al. 2008). A few years
later, Marie and Clunet observed the capacity of tumour
surgical resection to enhance cancer growth at metastasis
sites, an observation later confirmed both experimentally
and in some patients (Demicheli et al. 2008). One mecha-
nistic explanation for the inhibition of metastasis growth by
tumour mass was provided more than 80 years later. It was
demonstrated that, in the experimental models of cancer
used, the primary tumours produce and release angiostatin,
an an t i - ang iogen ic f ac to r su f f i c i en t to induce
micrometastasis dormancy (O’Reilly et al. 1994; Holmgren
et al. 1995; Guba et al. 2001). The observed effect is a
systemic prophylactic process. It originates in the primary
tumour and provides one explanation for the existence of
latent carcinoma and spontaneous tumour regression.
Unfortunately, pro-angiogenic factors are also produced by
primary tumour. Shifting the balance between pro- and anti-
angiogenic factors in favour of angiogenesis is, in these
experimental models, the condition for tumour growth and
cancer disease.
These experiments unambiguously identify the produc-
tion of circulating anti-angiogenic factors by the tumour.
They illustrate one mechanism by which tumour can exert
a prophylactic potential. This does not question the thera-
peutic importance of tumour removal that decreases metas-
tasis incidence by suppressing the primary source of
metastasing cells. Nevertheless, this also raises the possibil-
ity that a systemic global cancer dormancy state could be
induced by a network of dormant prophylactic micro-
tumours mutually controlling their dormant state. If this
hypothesis turns to be correct, over-treating dormant tu-
mours might have the adverse effect of disrupting the regu-
lation of this cancer-suppressive network.
Other evidence that demonstrates the existence of mech-
anisms restraining local tumour progression and aggressive-
ness in the tumour have been recently produced. They
concern the interactions between the tumour and its stroma
(Bissell and Radisky 2001; Ozdemir et al. 2014; Rhim et al.
2014).
8.2 Protective function of tumour stroma in cancer disease
A tumour is made of cancer cells and stroma. Cellular
components of tumour stroma include fibroblasts and
cancer-associated fibroblasts, pericytes, smooth muscle cells
and endothelial and immune/inflammatory cells. All these
cells including cancer cells are embedded in a three-
dimensional protein-rich extracellular matrix (ECM). In the
current dominant paradigm, the tumour grows because stro-
ma components provide the appropriate tumour micro-
environment for this growth. A large amount of experiments
and clinical data support this view (Joyce 2005; Tlsty and
Coussens 2006; Arendt et al. 2010; Pietras and Ostman
2010). Hence, antagonizing stroma functions is considered
a promising therapeutic strategy (Albini and Sporn 2007;
Hiscox et al. 2011; Franco and Hayward 2012; Tchou and
Conejo-Garcia 2012). Evidence that the tumour micro-
environment restrains cancer progression exist (Bissell and
Radisky 2001; Bissell and Hines 2011; Quail and Joyce
2013; Ozdemir et al. 2014; Rhim et al. 2014). The recent
demonstration that attenuation of tumour stroma formation
leads to a more aggressive phenotype in experimental
models of pancreatic ductal adenocarcinoma (Ozdemir
et al. 2014; Rhim et al. 2014) is in agreement with this.
Tumour stroma is now viewed as a structure balancing
between anti- and pro-carcinogenic functions (Bissell and
Radisky 2001; Quail and Joyce 2013) .
9. Viewing cancer disease as an extracellular
pathology: Cancer is also an ECM disease
The concept of a cell is, strictly speaking, only a
morphological abstraction. Seen from a biological
viewpoint, a cell cannot be considered by itself without
taking its environment into account.
The idea that the micro-environment is involved in cancer
progression is not new. The 1889 Paget’s seminal ‘seed and
soil’ hypothesis pointed to the dependence of cancer cells
(the seed) on their environment (the soil) in the metastasis
– Alfred Pischinger
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process. Dvorak’s view that tumours are wounds that do not
heal also considers the role of stroma in tumour growth
(Dvorak 1986). The importance of considering cancer as a
problem of tissue disorganization that necessarily implies
micro-environment, and not exclusively as a cancer cell-
based disease, has been extensively discussed by Smithers,
Sonnenschein and Soto, and Bissel, among others (Smithers
1962; Bissell and Radisky 2001; Bissell and Hines 2011;
Sonnenschein and Soto 2011). A huge amount of experi-
mental and clinical data demonstrates the importance of the
tumour stroma micro-environment in cancer disease
(Mueller and Fusenig 2004; Joyce 2005; Bissell and Hines
2011; Quail and Joyce 2013). Targeting the tumour micro-
environment is considered a complementary strategy to can-
cer cell cytotoxic therapies (Joyce 2005; Kenny et al. 2007;
Ingber 2008; Allen and Louise Jones 2011).
Our conception of the role played by the micro-
environment in cancer has been partially biased for a long
time. Most initial studies focused on the supportive role of
stroma in tumour growth but less on its cancer-suppressive
functions. Even nowadays, ‘reactive’ tumour stroma is still
largely considered as an ‘activated’ micro-environment
made of ‘activated’ cells harboring ‘activated’ signalling
pathways. Cancer associated fibroblasts are considered as
‘activated’ because they support cancer growth. In the re-
versed perspective where stroma controls tissue homeostasis,
however, it is also the inhibition of the stroma cancer-
suppressive potential that makes cancer disease. This bipolar
function of stroma has been already discussed (Mueller and
Fusenig 2004; Bissell and Hines 2011). It is consistent with
the concept of the tumour prophylactic/pathologic continu-
um and provides one explanation for tumour dormancy.
As discussed above, one major component of cell stroma
is ECM. Because ECM is a non-cellular component, consid-
ering ECM as a causative factor for cancer disease intro-
duces an additional paradigm shift. Cancer is no longer
viewed exclusively as a cell-centered disease but also as an
extracellular pathology. As provocatively put by Smithers:
‘should we analyse individual cars to understand a traffic
jam?’ (Smithers 1962). From a functional standpoint, ECM
constitutes the dynamic scaffolding that gives physical sup-
port to cells. It is made of proteins, proteoglycans and
polysaccharides. In addition, ECM meshwork also plays a
critical role in controlling cell fate, notably during morpho-
genesis, tissue renewal, and repair in all tissues including
stem cell niches (Watt and Huck 2013; Gattazzo et al. 2014).
Mechanosensing and mechanotransduction are two of these
processes by which cells sense ECM mechanical and phys-
ical cues through cell transmembrane adhesive proteins such
as integrins, discoidin domain receptors and syndecan
(DuFort et al. 2011; Schiller and Fässler 2013). These inter-
actions activate many intracellular signal transduction path-
ways which control cell differentiation, proliferation and
migration (DuFort et al. 2011; Hoffman et al. 2011).
Two other families of ECM proteins critically involved in
controlling the flux of information between cells and ECM
are matrix metalloproteinases (MMPs) and their
endogeneous inhibitors called tissue inhibitors of metallo-
proteinase (TIMPs). MMPs are involved both in ECM turn-
over that remodels ECM scaffolding, and in the release of
ECM-sequestered growth factors such as VEGF, bFGF and
TGF-β. Importantly, MMPs have a dual effect as they also
release anti-angiogenic factors such as endostatin and
tumstatin from ECM and basement membrane components
(Hamano et al. 2003; Heljasvaara et al. 2005; Martin and
Matrisian 2007; Fukuda et al. 2011). The balance between
MMP and TIMP activities is therefore essential for tissue
homeostasis. Other matrix-associated proteins such as
lysyloxydases or transglutaminase also play critical func-
tions in modulating ECM structure (Kotsakis and Griffin
2007; Mayorca-Guiliani and Erler 2013).
These are only a few examples that show how ECM
organization and composition control cell behavior and tis-
sue homeostasis. Not surprisingly, during tumour progres-
sion, cancer associated fibroblasts, immune cells and cancer
cells induce profound remodeling of tumour ECM that in
turn influences the behavior of stromal cells. ‘Cells make
ECM, and ECM structures cell behavior’ (Bissell et al.
1982). For that reason, cells and ECM should not be viewed
as two distinct entities, but as components of a dynamic
system, the tumour prophylactic–pathologic continuum.
Any perturbation in ECM structure can alter tissue homeo-
stasis and can lead to cancer cell proliferation and spreading,
depending on the context. ECM remodeling is both a conse-
quence and a causal cofactor in the development of cancer.
Because it surrounds cancer cells, ECM can be viewed, at
least etymologically speaking, as the circumstance
(‘circum’-around + ‘stare’- to stand) of cancer. ECM is the
‘circumstance’ in which the cancer cell is embedded. It is
‘circumstance’ that makes tumour prophylactic, pathologic,
or indeterminate, all these three states coexisting in the same
tumour continuum.
10. Conclusions and perspectives: From paradigm
shifts to cancer prevention and therapy
The therapeutic challenges posed by many cancers remain.
Curing cancer is rare. Hence, the recurrent question is to
what extent a scientific problem can be solved in the para-
digm frameworks from which it originated. A possible way
to tackle the problem is to use the ‘paradigm shift’ as a
method of scientific inquiry. In the case of cancer research,
this first requires identifying which paradigms grounded its
emergence as a scientific object. Cancer research at end of
the 19th and the beginning of the 20th centuries incorporated
most of the conceptual, experimental and technological prin-
ciples issued from microbiological medicine. The logical
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implication of this ‘microbiological framework’ is that can-
cer appeared as an ersatz of infectious disease in which
cancer cells are isolated and then conceptualized as organ-
isms, i.e. microbe avatars. Application of the ‘paradigm
shift’ principle as a method of investigation introduces sev-
eral reversals of perspective, with implications in both cancer
prevention and treatment.
A first paradigm shift views the tumour as a prophylactic–
pathologic continuum. The fact that the tumour is embedded
with prophylactic potential and that cancer is the reversal of
this prophylactic potential into a pathologic one enlightens
one challenge encountered by some targeted therapies. A
prevision of the tumour prophylactic–pathologic continuum
is that the same molecule or process viewed as a therapeutic
target at the pathologic edge of the continuum could also
behave as an anti-target at the prophylactic opposite end. For
example, VEGF is a therapeutic target but is also anti-target
since hypoxia can increase the tumour cancer stem cell pool
and fuels metastasis (Loges et al. 2009; Conley et al. 2012;
Nugue and Wion 2012). Some MMPs, initially considered as
therapeutic targets for their role in EMC remodeling and
cancer invasion are also viewed as anti-targets in regard to
their ability to release anti-angiogenic and anti-inflammatory
molecules (Dufour and Overall 2013). Likewise for the
bipolar function of TGFβ: cancer-suppressive at one end of
the continuum and involved in cancer progression at the
other end (Ikushima and Miyazono 2010; Pickup et al.
2013; Principe et al. 2014). An additional example is pro-
vided by certain oncogenes that govern proliferation and
senescent and apoptotic processes. Ras oncogene-induced
senescence or Myc induced-apoptosis illustrate how onco-
genes can be either targets or anti-targets, depending on the
context (secondary lesions, micro-environment, etc.) (Lowe
et al. 2004) . Indeed, the fact that a PubMed search with the
keywords ‘friend, foe, cancer’ generates almost 200 entries
is an indirect assessment of the relevance of the target/anti-
target challenge in cancer therapy.
Another paradigm shift leads us to consider cancer as an
extracellular pathology. As extensively discussed above,
cancer disease was for a long time exclusively considered a
cell disease at the expense of the role played by extra-cellular
matrix. The role of ECM in cancer disease is nowadays
acknowledged. Cancer can no longer be considered exclu-
sively as a ‘cellular pathology’. A systematic use of the
‘paradigm shift’ principle to question our dominant para-
digms could have greatly accelerated the discovery that
cancer is also an extracellular pathology, namely a disease
of interactions, and the role played by the extracellular
matrix in this process. A consequence of this paradigm shift
is that identifying potential ECM-disrupting compounds in
household and industrial products should be now a major
public health concern. Also, it is important to note that a
side-effect of almost all cancer therapies is to alter ECM
mesh work and that, to date, none of cancer therapy has
demonstrated any efficiency in repairing ECM structure and
restoring its homeostasis function. These points must be
integrated into future therapeutic protocols.
A third paradigm shift concerns cancer therapy. The
search for targeted therapies (‘magic bullets’) aims to target
special cells or specific cell functions. Application of the
‘paradigm shift’ method leads to a reversal of perspective in
which cancer cells are no longer considered the target but the
‘magic bullet’ itself. This paradigm shift gave birth to the
development of the cancer cell trap or tumour trap concepts,
in which cancer cells are the ‘bullets’ that target a therapeutic
trap where cancer cells are eliminated (van der Sanden et al.
2013; Jain et al. 2014). These are just a few examples
illustrating the potential of the ‘paradigm shift’ as a method.
Finally, the ultimate paradigm shift could come from a 2500
year old quote attributed to Sun Tzu: ‘The supreme art of war
is to subdue the enemy without fighting’. Rather than serv-
ing the cancer war machine, it is time to rethink the problem
of cancer therapy in terms of diplomacy.
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